How Seres CEO Roger Pomerantz went from an infectious disease doctor to mining the microbiome for drugs.
Want to get an ethicist agitated? Mention the integration of voice-activation and other tech into healthcare. Experts say navigating this area is a work in progress.
The general sense: Nobody should get comfortable with the status quo
Pfizer persuades Read to stay another year; House GOP to take another crack at "right to try"; Lundbeck plans to acquire Prexton Therapeutics.
FDA moves to limit nicotine in cigarettes; Alexion reports positive test for rare blood disorder treatment; Oregon governor signs drug pricing transparency bill.
MM&M spoke with Gazzaley about what's next for Akili, how he defines "digital medicine," and where the field is currently positioned on the hype cycle.
Why the U.S. spends more on healthcare with worse results; Alnylam goes it alone on rare disease therapy; MorphoSys hopes for accelerated approval on MOR208.
UnitedHealth names Witty as Optum CEO; Gilead R&D chief to exit; Novartis ups chief digital officer to executive committee.
Direct-to-consumer drug marketing spend dropped most heavily in the magazine and digital categories.
Health's popularity at SXSW continues to build. Here's our opening weekend wrap-up.
Regeneron, Sanofi cut cost of Praluent for wider coverage; GSK to maintain Advair exclusivity for 2018; 'Right to try' bill introduced in House.
White House quashes Idaho's insurance plans; Voyager reports positive results in clinical trial for Parkinson's drug; Cigna-Express Scripts deal to face long review.
Now more than ever, patients aren't shy about sharing their wants and needs. Here, 8,000 patients from three generations in the U.S., U.K., Germany, and France weigh in on everything from brand loyalty to the factors that drive their decision-making-processes to the reasons they switch treatments.
She was one of the firm's original staffers in 2013.
The NY-based shop is known as BX: Brand Experience Design Group.
Cigna to buy Express Scripts for $52B; Gottlieb says 'rigged' system is keeping drug prices high; Sanofi, Evotec speed up infectious disease research.
As oncology drugs save or extend the lives of many more patients than anyone could have imagined a few years ago, a new challenge has emerged in the wake of their approval: Selling them to patients scared about their prognosis and alternately ignorant of and skeptical about recent breakthroughs in treatment.
FDA approves 23andMe breast cancer test, with a warning; Novartis partners with Science 37 on clinical trials using mobile devices; European regulator calls for suspension of Zinbryta.